DEVELOPMENT OF NOVEL TUMOR IMAGING AGENTS

新型肿瘤显像剂的开发

• 批准号: 6030094
• 负责人: EDWARD F PATZ
• 金额: $ 14.97万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-03-07 至 2002-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6030094
• 关键词: binding proteins; combinatorial chemistry; drug design /synthesis /production; ligands; neoplasm /cancer radionuclide diagnosis; peptide library; positron emission tomography; radiotracer; reagent /indicator; receptor binding; single photon emission computed tomography

DESCRIPTION (Adapted from Applicant's Abstract): Cancer remains a major health problem and financial burden on the medical system. While conventional radiologic studies provide an important roadmap for pathologic diagnosis and staging, they often represent the limiting step in our ability for early and accurate detection of disease. If there is to be a significant impact on cancer, there is a need to pursue new strategies to include and utilize a growing knowledge of tumor genetics, molecular biology, and biochemistry in an effort to design new tumor specific imaging agents. Development of a noninvasive imaging study capable of early detection and accurate staging has overwhelming clinical and economic implications. Nuclear medicine studies (SPECT of PET) with tumor specific agents have the potential to be orders of magnitude more accurate then other non-invasive studies, including serum markers and conventional imaging techniques. These studies can provide metabolic, biochemical, physiologic, and anatomic information. Current imaging agents, however, are not uniformly specific or sensitive, and thus this project will continue development of novel small molecules in an effort to design a radiolabeled ligand for cancer imaging. While these efforts specifically focus on a mutant tumor receptor system as a model, the proposed approach for ligand discovery with combinatorial chemistry libraries is applicable to other tumors as well. This type of translational research is absolutely essential if improved outcomes of this devastating disease are to be realized.

描述（改编自申请人的摘要）：癌症仍然是一个主要的健康问题。 医疗系统的问题和财政负担。虽然常规 放射学研究为病理诊断提供了重要的路线图， 分期，他们往往代表了我们的能力的限制步骤， 准确检测疾病。如果有重大影响， 癌症，有必要寻求新的战略，包括和利用 肿瘤遗传学、分子生物学和生物化学知识的不断增长， 努力设计新的肿瘤特异性成像剂。发展 能够早期检测和准确分期的非侵入性成像研究 巨大的临床和经济影响。核医学研究 （PET的SPECT）与肿瘤特异性药物有可能是订单 比其他非侵入性研究更准确，包括血清 标记和常规成像技术。这些研究可以提供 代谢、生化、生理和解剖信息。当前成像 然而，代理商并不是统一的特异性或敏感性，因此该项目 将继续开发新的小分子，努力设计一种 放射性标记的配体用于癌症成像。虽然这些努力特别侧重于 以突变型肿瘤受体系统为模型，提出了配体的方法， 组合化学文库的发现适用于其他肿瘤 也这种类型的翻译研究是绝对必要的，如果 这一毁灭性疾病的治疗结果有待改善。